164 related articles for article (PubMed ID: 24368590)
1. Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination.
Ugur HC; Taspinar M; Ilgaz S; Sert F; Canpinar H; Rey JA; Castresana JS; Sunguroglu A
Mol Biol Rep; 2014 Feb; 41(2):697-703. PubMed ID: 24368590
[TBL] [Abstract][Full Text] [Related]
2. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Naumann SC; Roos WP; Jöst E; Belohlavek C; Lennerz V; Schmidt CW; Christmann M; Kaina B
Br J Cancer; 2009 Jan; 100(2):322-33. PubMed ID: 19127257
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor enhances effect of temozolomide on high-grade glioma cells.
Yang D; Cheng X; Bu X; Yan Z; Wu T; Zhang Y
Anticancer Drugs; 2020 Oct; 31(9):950-958. PubMed ID: 32590393
[TBL] [Abstract][Full Text] [Related]
5. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
6. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
[TBL] [Abstract][Full Text] [Related]
8. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.
van Nifterik KA; van den Berg J; van der Meide WF; Ameziane N; Wedekind LE; Steenbergen RD; Leenstra S; Lafleur MV; Slotman BJ; Stalpers LJ; Sminia P
Br J Cancer; 2010 Jun; 103(1):29-35. PubMed ID: 20517307
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a novel anti-cancer compound for astrocytomas.
Lee SY; Slagle-Webb B; Rizk E; Patel A; Miller PA; Sung SS; Connor JR
PLoS One; 2014; 9(9):e108166. PubMed ID: 25255031
[TBL] [Abstract][Full Text] [Related]
10. Lomeguatrib Increases the Radiosensitivity of MGMT Unmethylated Human Glioblastoma Multiforme Cell Lines.
Kirstein A; Schilling D; Combs SE; Schmid TE
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202589
[TBL] [Abstract][Full Text] [Related]
11. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
13. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
[TBL] [Abstract][Full Text] [Related]
14. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
[TBL] [Abstract][Full Text] [Related]
15. Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O
Dehghani-Soltani S; Eftekhar-Vaghefi SH; Babaee A; Basiri M; Mohammadipoor-Ghasemabad L; Vosough P; Ahmadi-Zeidabadi M
Cancer Biother Radiopharm; 2021 Sep; 36(7):579-587. PubMed ID: 32644826
[No Abstract] [Full Text] [Related]
16. Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.
De Salvo M; Maresca G; D'agnano I; Marchese R; Stigliano A; Gagliassi R; Brunetti E; Raza GH; De Paula U; Bucci B
Int J Radiat Biol; 2011 May; 87(5):518-33. PubMed ID: 21405945
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Ryu CH; Yoon WS; Park KY; Kim SM; Lim JY; Woo JS; Jeong CH; Hou Y; Jeun SS
J Biomed Biotechnol; 2012; 2012():987495. PubMed ID: 22701311
[TBL] [Abstract][Full Text] [Related]
18. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Spiegl-Kreinecker S; Pirker C; Filipits M; Lötsch D; Buchroithner J; Pichler J; Silye R; Weis S; Micksche M; Fischer J; Berger W
Neuro Oncol; 2010 Jan; 12(1):28-36. PubMed ID: 20150365
[TBL] [Abstract][Full Text] [Related]
19. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
von Bueren AO; Bacolod MD; Hagel C; Heinimann K; Fedier A; Kordes U; Pietsch T; Koster J; Grotzer MA; Friedman HS; Marra G; Kool M; Rutkowski S
Br J Cancer; 2012 Oct; 107(8):1399-408. PubMed ID: 22976800
[TBL] [Abstract][Full Text] [Related]
20. Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma.
Tezcan G; Tunca B; Demirci H; Bekar A; Taskapilioglu MO; Kocaeli H; Egeli U; Cecener G; Tolunay S; Vatan O
Nutr Cancer; 2017; 69(6):873-880. PubMed ID: 28718668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
